Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Pinpoints Culprit In Bad Heparin

This article was originally published in The Pink Sheet Daily

Executive Summary

Over-sulfated chondroitin sulfate named as adverse-events link, but China disagrees.

You may also be interested in...



FDA Cracks Down On Unregistered Foreign Pharmaceutical Manufacturers

The agency has sent 11 warning letters for failure to register and list as importers of drugs into the U.S. since the beginning of the year.

FDA’s Poor Performance “Invites Catastrophe,” House Investigator Says

Good public health response, poor regulatory oversight mark adulterated heparin episode, Nelson testifies.

FDA’s Poor Performance “Invites Catastrophe,” House Investigator Says

Good public health response, poor regulatory oversight mark adulterated heparin episode, Nelson testifies.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel